Source: Annual Congress 2003 - Molecular biology of chronic lung disease and lung cancer
Disease area: Thoracic oncology

Abstract

Materials and methods: In this study took part 33 patients with histological lung cancer defined. TNM classification, clinical stages and therapeutic effect was performed in UICC, AJCC, WHO (1997) standards. The specimens were taken before and after 4 cycles of chemotherapy during bronchofiberoscopy. Bronchial biopsy specimens were examined histological and when neoplasmatic cells were found they were analyze in flow cytometer. Histograms were analyzed for DNA ploidy, S-phase fraction, G2/M fraction using Multicycle software. Statistical analysis was done using Statistica 5.0 software.
Results: The percentage of aneuploid cells was still high after chemotherapy in comparison to percentage of normal (diploid) cells. The percentage of S-phase cells keeps high in spite of chemotherapy, percentage of G2/M phase cells was significant decreased after chemotherapy. There were no relationship between percentage of aneuploid cells and T,N and M marks. Clinical stages did not have influence on percentages of diploid and aneuploid cells before chemotherapy. Patients in III B stage had significant lower the percentage of G2/M phase cells and significant higher the percentages of S phase cells after chemotherapy than before.
Conclusions: Clinical stages and TNM classification have no influence on DNA ploidy in patients with NSCLC in more advanced stages. After chemoterapy, there is still high percentage of aneuploid cells and S phase cells.

Rating:

Share or cite this content

Citations should be made in the following way:
T. Izycki, E. Chyczewska, R. M. Mroz, W. Naumnik (Bialystok, Poland). Assessment of DNA ploidy and proliferating activity changes in neoplasmatic cells according to TNM classification and clinical stages in non-small cell lung cancer (NSCLC) patients during chemotherapy. Eur Respir J 2003; 22: Suppl. 45, 1509

Member's Comments

No comment yet.

Related content which might interest you: Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002 Different expression of miRNA in non-small cell lung cancer according to its clinical stage Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP) Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC) Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010 Staging of lung cancer Source: Eur Respir Mon; 2009: 44: 150–168 Year: 2009 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008